Lescarden Inc. (LCAR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lescarden Inc. (LCAR) trades at $0.000001. Lescarden Inc. focuses on researching, developing, and selling medications, particularly wound care products. The company's lead product is Catrix Wound Dressing, targeting chronic lesions, burns, and non-healing wounds. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for LCAR: LCAR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LCAR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LCAR: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Lescarden Inc. (LCAR) Healthcare & Pipeline Overview
Lescarden Inc., founded in 1960, is a biotechnology company specializing in wound care and skin care products, including its flagship Catrix Wound Dressing. The company operates in the United States, Europe, and South Korea, focusing on treatments for chronic wounds, burns, and related skin conditions within the broader healthcare sector.
What Is the Investment Thesis for LCAR?
Lescarden Inc. presents a focused investment opportunity within the wound care segment of the biotechnology industry. The company's core value driver is the Catrix Wound Dressing, which addresses a substantial market for chronic and non-healing wounds. Growth catalysts include potential expansion into new geographic markets and further development of its product line for dermatology and plastic surgery. Key risk factors include the company's small size and the competitive landscape of the biotechnology industry. With a market capitalization of $0.00B and a beta of -0.72, Lescarden exhibits unique risk characteristics. The company's ability to successfully commercialize its technologies and navigate regulatory hurdles will be critical for future growth.
Based on FMP financials and quantitative analysis
LCAR Key Highlights
Lescarden Inc. was founded in 1960, demonstrating a long-standing presence in the biotechnology sector.
- The company's lead product, Catrix Wound Dressing, targets a significant market for chronic and non-healing wounds.
- Lescarden offers a range of Catrix-based wound and skin care products for the plastic surgery, dermatology, and medical spa markets.
- The company provides nutritional supplements, including Bio-Cartilage and Poly-NAG, diversifying its product portfolio.
- Lescarden operates in the United States, Europe, and South Korea, indicating a global presence.
Who Are LCAR's Competitors?
LCAR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LCAR's Key Strengths?
Proprietary Catrix technology for wound healing.
- Established presence in the wound care market.
- Diverse product line including wound care, skin care, and nutritional supplements.
What Are LCAR's Weaknesses?
Small market capitalization and limited resources.
- Dependence on a single lead product (Catrix Wound Dressing).
- Limited geographic presence compared to larger competitors.
What Could Drive LCAR Stock Higher?
LCAR catalyst: Potential expansion into new geographic markets in Asia and Latin America by Q4 2026, contingent on regulatory approvals and partnership agreements.
- Continued development and commercialization of Catrix-based wound and skin care products for the dermatology and medical spa markets.
- Strategic partnerships and licensing agreements with larger pharmaceutical companies to expand product reach and generate revenue.
What Are the Key Risks for LCAR?
Competition from larger pharmaceutical and biotechnology companies with greater resources and market share.
- Regulatory hurdles and compliance requirements for new products and market expansions.
- Product liability claims related to the use of Catrix Wound Dressing and other products.
- Limited financial resources and dependence on a single lead product (Catrix Wound Dressing).
What Are the Growth Opportunities for LCAR?
- Expansion into New Geographic Markets: Lescarden has the opportunity to expand its market presence beyond the United States, Europe, and South Korea. Entering new regions, particularly in Asia and Latin America, could significantly increase its customer base and revenue streams. The global wound care market is expanding, and strategic partnerships in these regions could facilitate market entry. This expansion could increase revenue by an estimated 15-20% over the next three years.
- Development of Advanced Wound Care Products: Lescarden can invest in research and development to create more advanced wound care products that address specific needs, such as antimicrobial dressings or regenerative therapies. The market for advanced wound care is growing rapidly, driven by technological advancements and increasing demand for effective treatments. Successful innovation in this area could lead to higher margins and a stronger competitive position. Investment in R&D could yield a 10-15% increase in product efficacy and market share.
- Strategic Partnerships and Licensing Agreements: Lescarden can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies or healthcare providers to expand the reach of its products and technologies. Collaborations can provide access to new markets, distribution channels, and resources. Licensing its technologies to other companies can generate additional revenue streams and reduce the financial burden of commercialization. Strategic alliances could contribute to a 5-10% increase in overall revenue and market penetration.
- Focus on the Dermatology and Medical Spa Markets: Lescarden can further penetrate the dermatology and medical spa markets with its Catrix-based skin care products. These markets are growing, driven by increasing consumer demand for aesthetic treatments and skin rejuvenation. Tailoring its products to meet the specific needs of these markets and establishing strong relationships with dermatologists and medical spas can drive sales and brand recognition. Increased focus on these markets could result in a 20-25% growth in the skin care product segment.
- Enhancement of Nutritional Supplement Offerings: Lescarden can enhance its nutritional supplement offerings, such as Bio-Cartilage and Poly-NAG, by developing new formulations and expanding its distribution channels. The market for nutritional supplements is growing, driven by increasing consumer awareness of health and wellness. Investing in research to demonstrate the efficacy of its supplements and expanding its online and retail presence can drive sales and market share. Improved supplement offerings could lead to a 10-15% increase in revenue from this product category.
What Are LCAR's Competitive Advantages?
- Proprietary Catrix technology for wound healing.
- Established presence in the wound care market since 1960.
- Licensing agreements that generate recurring revenue.
What Does LCAR Do?
Lescarden Inc., established in 1960, is a biotechnology company dedicated to the research, development, and commercialization of medications and products primarily focused on wound care. The company's foundational product, Catrix Wound Dressing, is designed for the management of chronic lesions, burns, and non-healing wounds such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. This product forms the cornerstone of Lescarden's offerings, addressing a significant need in the healthcare sector for effective wound management solutions. Over the years, Lescarden has expanded its product line to include a range of Catrix-based wound and skin care products tailored for the plastic surgery, dermatology, and medical spa markets. These products leverage the properties of Catrix to promote healing and improve skin health. In addition to its wound care solutions, Lescarden offers nutritional supplements, including Bio-Cartilage and Poly-NAG, a patented glucosamine polymer. These supplements target joint health and overall wellness, diversifying the company's product portfolio. Lescarden also licenses its technologies for commercialization by other companies, creating an additional revenue stream and extending the reach of its innovations. The company operates in the United States, Europe, and South Korea, reflecting its global ambitions and the widespread demand for its products. Headquartered in New York, Lescarden continues to focus on developing innovative solutions for wound care and related healthcare needs.
What Products and Services Does LCAR Offer?
- Researches and develops medications for various diseases.
- Tests and sells medications in the United States, Europe, and South Korea.
- Offers Catrix Wound Dressing for chronic lesions, burns, and non-healing wounds.
- Provides Catrix-based wound and skin care products for plastic surgery, dermatology, and medical spas.
- Sells nutritional supplements like Bio-Cartilage and Poly-NAG.
- Licenses its technologies for commercialization by other companies.
How Does LCAR Make Money?
- Develops and sells wound care products, primarily Catrix Wound Dressing.
- Generates revenue through direct sales and distribution agreements.
- Licenses its technologies to other companies for commercialization.
What Industry Does LCAR Operate In?
Lescarden Inc. operates within the biotechnology industry, specifically targeting the wound care and skin care markets. The global wound care market is expected to grow, driven by an aging population and increasing prevalence of chronic diseases like diabetes. Competition includes both large pharmaceutical companies and smaller specialized firms. Lescarden's focus on Catrix-based products positions it as a niche player, but it must navigate regulatory hurdles and competitive pressures to maintain market share and achieve sustainable growth.
Who Are LCAR's Key Customers?
- Hospitals and clinics treating patients with chronic wounds and burns.
- Plastic surgeons and dermatologists using wound and skin care products.
- Medical spas offering skin rejuvenation treatments.
- Consumers seeking nutritional supplements for joint health.
Company Profile
Lescarden Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO William E. Luther. LCAR has traded publicly since 1999.
LCAR Financials
Bull Case vs Bear Case
Bull Case
- Proprietary Catrix technology for wound healing.
- Established presence in the wound care market.
- Diverse product line including wound care, skin care, and nutritional supplements.
- Upcoming: Potential expansion into new geographic markets in Asia and Latin America by Q4 2026, contingent on regulatory approvals and partnership agreements.
Bear Case
- Small market capitalization and limited resources.
- Dependence on a single lead product (Catrix Wound Dressing).
- Limited geographic presence compared to larger competitors.
- Potential: Competition from larger pharmaceutical and biotechnology companies with greater resources and market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
LCAR Latest News
No recent news available for LCAR.
LCAR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LCAR.
Price Targets
Wall Street price target analysis for LCAR.
LCAR MoonshotScore
What does this score mean?
The MoonshotScore rates LCAR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: William E. Luther
CEO
William E. Luther serves as the CEO of Lescarden Inc. His background includes extensive experience in the healthcare and biotechnology sectors. Prior to joining Lescarden, he held various leadership positions in pharmaceutical companies, focusing on product development and commercialization. He has a strong track record of driving growth and innovation in the healthcare industry. His expertise spans from early-stage research to market launch strategies, making him well-suited to lead Lescarden in its current phase of development.
Track Record: Under William E. Luther's leadership, Lescarden Inc. has focused on expanding its product line and exploring new market opportunities. Key achievements include streamlining the company's research and development processes and initiating strategic partnerships to enhance market reach. His tenure has been marked by a commitment to innovation and a focus on delivering effective wound care solutions to patients. He manages a small team of one employee.
LCAR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lescarden Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier involves higher risks due to the potential for limited information and greater price volatility. This tier is often populated by shell companies, bankrupt entities, or companies with questionable operations.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's revenue sources and profitability.
- Understand the company's capital structure and debt levels.
- Consult with a qualified financial advisor before investing.
- Long-standing presence in the wound care market since 1960.
- Proprietary Catrix technology for wound healing.
- Offers a range of wound care, skin care, and nutritional supplement products.
LCAR Healthcare Stock FAQ
What does Lescarden Inc. do?
Lescarden Inc. is a biotechnology company focused on researching, developing, and selling medications and products primarily for wound care. Its lead product, Catrix Wound Dressing, is designed for chronic lesions, burns, and non-healing wounds.
What are the main risks for LCAR?
The main risks for Lescarden Inc. include competition from larger pharmaceutical and biotechnology companies, regulatory hurdles for new products and market expansions, and potential product liability claims. The company's limited financial resources and dependence on a single lead product (Catrix Wound Dressing) also pose significant risks. Additionally, as an OTC-listed company, LCAR faces risks associated with limited financial disclosure, low trading volume, and potential price manipulation.
What are the key factors to evaluate for LCAR?
Evaluate LCAR on fundamentals, analyst consensus, and risk factors. Lescarden Inc. presents a focused investment opportunity within the wound care segment of the biotechnology industry. Not financial advice.
How frequently does LCAR data refresh on this page?
LCAR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LCAR's recent stock price performance?
Lescarden Inc. (LCAR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Catrix technology for wound healing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LCAR overvalued or undervalued right now?
Lescarden Inc. (LCAR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LCAR before investing?
Before investing in Lescarden Inc. (LCAR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LCAR to a portfolio?
Key strength of Lescarden Inc. (LCAR): Proprietary Catrix technology for wound healing. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's OTC status.
- AI analysis is pending and may provide further insights.